Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer

Sponsor
Yongchang Zhang
Study ID
NCT03652857
Phase
PHASE2
Status
Completed

Conditions

  • Advanced Non Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to assess the safety and effectiveness of Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Posterior Advanced Non-small Cell Lung Cancer

Key Dates

Start date
Jan 1, 2017
Status verified
Feb 2020
Primary completion
Nov 30, 2018
Completion
Dec 31, 2019

Study Design

Enrollment
30 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib Combined With Vinorelbine
    Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer

Primary Outcome Measure

ORR [ Time Frame: Approximately 1 years ]

Related Studies